Total Product Registrations
3,111
+161 YoY
As on 31st March 2026, total product registrations stood at 3,111, with 1,104 applications in pipeline.
SHARDACROPCHEM
Other
15 May 2026
Sharda Cropchem Ltd — Q4 FY26
Sharda Cropchem delivered a stellar Q4 FY26, with revenue growing 13% YoY to ₹2,065 crore, EBITDA surging 75% to ₹513 crore (margin 24.8%, up 750bps), and PAT rising 57% to ₹319 crore.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Sharda Cropchem delivered a stellar Q4 FY26, with revenue growing 13% YoY to ₹2,065 crore, EBITDA surging 75% to ₹513 crore (margin 24.8%, up 750bps), and PAT rising 57% to ₹319 crore. The full year saw revenue of ₹5,268 crore (+22% YoY) and PAT of ₹681 crore (+124% YoY). Growth was driven by volume expansion (+4.3% in Q4, +13.4% full year) and favorable forex (+11.7% in Q4), partially offset by negative price/mix (-3.0%). Gross margins expanded 750bps to 37.3% due to better product mix and pricing discipline. Management guided FY27 revenue growth of 10-15%, gross margins around 35%, and EBITDA margins of 18-20%. Key risks include geopolitical uncertainty from the Middle East war and potential raw material price increases, though management believes 80-90% of cost increases can be passed on due to limited competition from registration barriers.
Key Numbers
Volume Growth (Q4)
4.3%
+4.3pp YoY
Volume growth for Q4 FY26 was 4.3% year-on-year, driven by Europe and Latam.
Working Capital Days
98 days
-20 days YoY
Working capital days improved to 98 days as on 31st March 2026 from 118 days a year ago.
Cash & Liquid Investments
₹702 crore
N/A
Company remains debt-free with cash and liquid investments of ₹702 crore as on 31st March 2026.
Management Guidance
Revenue growth 10-15% for FY27
Management expects revenue to grow by 10-15% in FY27, driven by volume growth of around 15% and stable pricing.
Management guidance revenueGross margins around 35% for FY27
Gross margins are expected to stay around 35% plus or minus a few percentage points, similar to FY26 levels.
Management guidance marginsEBITDA margins 18-20% for FY27
EBITDA margins are guided to be in the range of 18-20% for FY27, down from 24.8% in Q4 but consistent with full-year FY26 levels.
Management guidance marginsEffective tax rate 18-20% for FY27
The effective tax rate is expected to be between 18-20% for FY27, similar to recent trends.
Management guidance otherKey Risks
Geopolitical uncertainty from Middle East war
The ongoing war in the Middle East creates uncertainty in supply chains and raw material availability, though no major impact seen yet.
medium · management_commentaryRaw material price increases from China
Potential spike in Chinese agrochemical prices could pressure margins, though management believes 80-90% can be passed on.
medium · analyst_questionForex volatility impact on margins
Unrealized forex losses of ₹26 crore in Q4 highlight exposure to currency fluctuations, especially USD/EUR.
medium · analyst_questionRegistration delays impacting new product launches
Bureaucratic delays in product registrations could slow revenue contribution from new molecules, though management downplays impact.
low · analyst_questionNotable Quotes
FY 2025-26 has been by every measure the best year in Sharda Cropchem's history as a listed company.
Normally we are able to pass because the competition is limited. We are not dealing with products which are freely tradable and registration process is very expensive and time consuming.
We are having not more than 5% of that market share globally... we have a lot of scope to improve market share if it goes from 5% to 6% it's almost 20% increase in Sharda's business.
Frequently Asked Questions
What was Sharda Cropchem's revenue in Q4 FY26?
Sharda Cropchem reported revenue of ₹2,065 Cr in Q4 FY26, representing a +13% change compared to the same quarter last year.
What guidance did Sharda Cropchem management give for FY27?
Revenue growth 10-15% for FY27: Management expects revenue to grow by 10-15% in FY27, driven by volume growth of around 15% and stable pricing. Gross margins around 35% for FY27: Gross margins are expected to stay around 35% plus or minus a few percentage points, similar to FY26 levels. EBITDA margins 18-20% for FY27: EBITDA margins are guided to be in the range of 18-20% for FY27, down from 24.8% in Q4 but consistent with full-year FY26 levels. Effective tax rate 18-20% for FY27: The effective tax rate is expected to be between 18-20% for FY27, similar to recent trends.
What are the key risks for Sharda Cropchem in FY27?
Key risks include Geopolitical uncertainty from Middle East war — The ongoing war in the Middle East creates uncertainty in supply chains and raw material availability, though no major impact seen yet.; Raw material price increases from China — Potential spike in Chinese agrochemical prices could pressure margins, though management believes 80-90% can be passed on.; Forex volatility impact on margins — Unrealized forex losses of ₹26 crore in Q4 highlight exposure to currency fluctuations, especially USD/EUR.; Registration delays impacting new product launches — Bureaucratic delays in product registrations could slow revenue contribution from new molecules, though management downplays impact..
Did Sharda Cropchem meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Sharda Cropchem Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.